Cancer is a complex disease wherein cells begin to divideabnormally and spread into surrounding tissues. Angiogenesis plays a crucial role in
tumor progression as it is required for sustained growth and
metastasis, therefore targeting angiogenesis is a promising therapeutic approach for
breast cancer management.
Salinomycin (SAL) has been reported to exhibit anticancer response on various types of
cancer. In the present study, we explored the antiangiogenic and anticancer efficacy of the polyether
ionophore SAL in the
breast cancer model. It effectively inhibited cell proliferation, invasion, and migration. It also inhibited the expression of pro-angiogenic cell surface marker CD31 in HUVEC, thereby interrupting the endothelial tubulogenesis. It decreased the HIF-1α
transcription factor DNA binding activity to HRE sequence in HUVEC and human
breast cancer cells. Further, corresponding to our in vitro findings, SAL suppressed neovascularization in the chick chorioallantoic membrane and the
Matrigel plug implanted mice model. Bioluminescence and immunofluorescence imaging revealed that SAL treatment in mice inhibits
breast cancer growth and
tumor angiogenesis. SAL also suppressed the serum VEGFA level in
tumor-bearing mice and induced caspase-dependent apoptosis in
breast cancer cells. Taken together our findings suggested that SAL inhibits
VEGF induced angiogenesis and
breast cancer growth via interrupting HIF-1α/
VEGF signalling and could be used as a promising
antiangiogenic agent for
breast cancer treatment.